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Objective
To explore preferences in the management of patients with
newly diagnosed high-risk prostate cancer (PCa) among
urologists in Europe through a web-based survey.
Materials and Methods
A web-based survey was conducted between 15 August and 15
September 2013 by members of the Prostate Cancer Working
Group of the Young Academic Urologists Working Party of
the European Association of Urology (EAU). A speciﬁc,
29-item multiple-choice questionnaire covering the whole
spectrum of diagnosis, staging and treatment of high-risk PCa
was e-mailed to all urologists included in the mailing list of
EAU members. Europe was divided into four geographical
regions: Central-Eastern Europe (CEE), Northern Europe
(NE), Southern Europe (SE) and Western Europe (WE).
Descriptive statistics were used. Diﬀerences among sample
segments were obtained from a z-test compared with the total
sample.
Results
Of the 12 850 invited EAU members, 585 urologists practising
in Europe completed the survey. High-risk PCa was deﬁned
as serum PSA ≥20 ng/mL or clinical stage ≥ T3 or biopsy
Gleason score ≥ 8 by 67% of responders, without signiﬁcant
geographical variations. The preferred single-imaging
examinations for staging were bone scan (74%, 81% in WE
and 70% in SE; P = 0.02 for both), magnetic resonance
imaging (53%, 72% in WE and 40% in SE; P = 0.02 and P =
0.01, respectively) and computed tomography (45%, 60% in SE
and 23% in WE; P = 0.01 for both). Pre-treatment predictive
tools were routinely used by 62% of the urologists, without
signiﬁcant geographical variations. The preferred treatment
was radical prostatectomy as the initial step of a multiple-
treatment approach (60%, 40% in NE and 70% in CEE;
P = 0.02 and P < 0.01, respectively), followed by external
beam radiation therapy with androgen deprivation therapy
(29%, 45% in NE and 20% in CEE; P = 0.01 and P = 0.02,
respectively), and radical prostatectomy as monotherapy (4%,
7% in WE; P = 0.04).When surgery was performed, the open
retropubic approach was the most popular (58%, 74% in CEE,
37% in NE; P < 0.01 for both). Pelvic lymph node dissection
was performed by 96% of urologists, equally split between a
standard and extended template. There was no consensus on
the deﬁnition of disease recurrence after primary treatment,
and much heterogeneity in the administration of adjuvant and
salvage treatments.
Conclusion
With the limitation of a low response rate, the present study is
the ﬁrst survey evaluating preferences in the management of
high-risk PCa among urologists in Europe. Although the
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deﬁnition of high-risk PCa was fairly uniform, wide variations
in patterns of primary and adjuvant/salvage treatments were
observed. These diﬀerences might translate into variations in
quality of care with a possible impact on ultimate oncological
outcome.
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Introduction
High-risk prostate cancer (PCa) accounts for up to 40% of
newly diagnosed cases, depending on the deﬁnition used [1,2].
Despite reﬁnement in patient selection and advances in
primary and adjuvant therapies, disease recurrence remains
substantial, aﬀecting >50% of patients within 10 years after
treatment and carrying a signiﬁcant risk of progression and
death [1,3].
In the absence of high-level evidence, the best management
approach for patients with high-risk PCa is still under debate.
Guidelines from several scientiﬁc societies [4,5] provide useful
information, but evidence as to compliance to these is scarce
and conﬂicting [6,7]. All too often, therefore, the ultimate
management of high-risk PCa is inﬂuenced by the individual
preference of the treating urologist, the presence of a
multidisciplinary institutional team, local availability of
diagnostic and therapeutic technology and other non-medical
factors, such as patient socio-economic status, geographical
area and medicolegal issues [8–10].
There remains a paucity of data on attitudes of treating
urologists in the contemporary PCa literature. In the present
study, we explored preferences in the management of patients
with newly diagnosed high-risk PCa among urologists
practising in Europe through a web-based survey.
Materials and Methods
On 15 August 2013, a speciﬁc web-based questionnaire created
on surveymonkey.com by members of the Prostate Cancer
Working Group of the Young Academic Urologists Working
Party of the European Association of Urology (EAU) was sent
by e-mail to 12 850 urologists who were included in the
mailing list of the EAU members.
Participants were invited to answer a multiple-choice
questionnaire including 29 items covering the whole
spectrum of diagnosis, staging and treatment of high-risk
PCa. Multiple responses were allowed only for a few
questions (Appendix S1).
Data collection was stopped 30 days later, on 15 September
2013. All data were processed and analysed using GfK©
Romania (GfK Group, Nuremberg, Germany) in accordance
with the International Chamber of Commerce/European
Society for Opinion and Market Research Code on Market
and Social Research [11]. To evaluate whether diﬀerences were
related to the geographical origin of respondents, Europe was
divided into four areas: Central Eastern Europe (CEE),
Northern Europe (NE), Southern Europe (SE) and Western
Europe (WE [Appendix S2]).
Descriptive statistics were used. Diﬀerences among sample
segments were obtained from a z-test compared with total
sample, performed at a 95% conﬁdence level. A ± 3.9%
sampling error was observed. All reported P values were
two-sided and statistical signiﬁcance was set at P = 0.05. SPSS
21.0 software was used for statistical analysis.
Results
Of the 12 850 invited EAU members, 9829 practised in
European countries, and 8234 were urologists. Of these, 585
(7%) completed the survey, 105 (18%) from CEE, 36 (6%)
from NE, 281 (48%) from SE and 163 (28%) fromWE.
Of the 585 urologists, 246 (42%) were based at an academic
hospital (56% in CEE and 28% in WE; P = 0.01 and P < 0.01,
respectively), and 153 (26%) practised in a regional hospital
(43% in WE and 11% in CEE; P = 0.01 and 0.02, respectively).
Of the respondents, 293 (50%) had > 10 years of experience in
PCa management, and 223 (38%) were high-volume surgeons,
deﬁned as performing >50 radical prostatectomies (RPs) per
year. The vast majority of respondents (498/585, 85%) worked
within a multidisciplinary team, mostly including oncologists,
radiation oncologists and radiologists, this percentage being
the highest in WE (98%) and the lowest in CEE (77%; P = 0.01
for both).
Definition and Clinical Staging
High-risk PCa was deﬁned as PSA ≥20 ng/mL or clinical
stage ≥ T3 or biopsy Gleason score ≥ 8 by the majority of
respondents (392/585, 67%), with no signiﬁcant geographical
variations (Fig. 1).
The most commonly performed imaging examinations for
clinical staging were bone scan (74%, 81% in WE and 70% in
SE; P = 0.02 for both), MRI (53%, 72% in WE and 40% in SE;
P = 0.02 and P = 0.01, respectively) and CT (45%, 60% in SE
and 23% in WE; P = 0.01 for both). Pre-treatment predictive
tools were used on a routine basis by 62% of the respondents,
without signiﬁcant geographical variations. Partin tables and
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D’Amico risk classiﬁcation were the most frequently used (50
and 41%, respectively, without signiﬁcant geographical
variations).
Initial Treatment
The preferred initial treatment was RP as part of a
multiple-treatment approach for 60% of the respondents (70%
in CEE and 40% in WE; P = 0.02 and P < 0.01, respectively),
followed by external beam radiation therapy (EBRT) with
androgen deprivation therapy (ADT) by 29% (45% in NE and
20% in CEE; P = 0.01 and P = 0.02, respectively), and RP as
monotherapy by 4% (7% in WE; P = 0.04 [Fig. 2]).
When treatment was RP, the open retropubic approach was
the most frequently adopted (58% overall, 74% in CEE
and 37% in WE; P < 0.01 for both [Fig. 3]). Attempted
nerve-sparing was systematically avoided by 60%
of the respondents (73% in SE and 47% in CEE; P = 0.02 for
both).
Pelvic lymph node dissection (PLND) was routinely
performed by 96% of respondents (98% in SE and 88% in NE;
P = 0.03 and P = 0.02, respectively). A standard (i.e. external,
internal and obturator nodes bilaterally) and extended (i.e.
common iliac, external, internal and obturator nodes
bilaterally) dissection template was equally adopted (31 and
30% of respondents, respectively), with no signiﬁcant
geographical variations (Fig. 4). Intra-operative frozen sections
during PLND were routinely performed by 13% of the
respondents (19% in CEE; P = 0.03), and 46% of respondents
(63% in WE; P = 0.02) abandoned RP if lymph node invasion
Fig. 1 Preferences for definition of high-risk prostate cancer. Numbers are proportions of respondents per geographical area. Total refers to the entire
European sample (N = 585). PFS, progression-free survival.
PSA ≥ 20 ng/mL or clinical
stage ≥ T3 or biopsy GS ≥ 8
Europe
(N = 585)
67 67 64 7268
28 27 29 2724
19 9 15 2817
15 9 12 2411
13 3 11 2110
6 7 6
= significantly higher than total
= significantly lower than total
7
3 2 43 3
Central Easterm
(N = 108)
Northern
(N = 33)
Southern
(N = 280)
Western
(N = 164)
PSA ≥ 20 ng/mL or clinical
stage ≥ T2b or biopsy GS ≥ 8
Biopsy Gleason score ≥ 8
Clinical stage ≥ T3 at DRE
Preoperative PSA ≥ 20 ng/mL
PSA velocity > 2 ng/mL/year
Nomogram 5-year PFS ≤ 50%
Fig. 2 Preferences for initial management of high-risk prostate cancer. Numbers are proportions of respondents per geographical area. Total refers to
the entire European sample (N = 585). EBRT, external beam radiation therapy.
Radical prostatectomy initially as
part of a multimodal treatment
Europe
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© 2014 The Authors
BJU International © 2014 BJU International 573
Survey of preferences in management of high‐risk PCa in Europe
was proven. Regarding the minimal nodal yield required for
an accurate PLND, opinions varied, with some respondents
(56%) considering that the minimum number should
exceed 10, and others (37%) judging that dissection of an
anatomically deﬁned pelvic region was more important than
lymph node count.
Definition and Treatment of Disease Recurrence
Biochemical recurrence (BCR) after RP was deﬁned as any
rise in PSA level ≥0.2 ng/mL, conﬁrmed with a second
measurement at least 1 month apart, by 47% of the
respondents, while 26% deﬁned BCR as three consecutive
rises of PSA ≥0.2 ng/mL (Fig. 5). No signiﬁcant geographical
variations were observed.
Regarding the deﬁnition of local recurrence after RP,
responses varied from a positive biopsy from anastomosis
site/pelvis (32%) to abnormal ﬁndings on MRI (29%) and
to positive surgical margins (24%), with no signiﬁcant
geographical variations (Fig. 6).
In all, 47% of the respondents deﬁned BCR after EBRT as any
rise in PSA level ≥2 ng/mL above the post-treatment nadir,
while 37% of respondents deﬁned it as three consecutive
PSA rises above the post-treatment nadir. No signiﬁcant
geographical variations were observed.
Concerning adjuvant/salvage treatment after RP, 53% of
respondents (63% in SE and 36% in NE; P = 0.02 and P = 0.01,
respectively) oﬀered adjuvant EBRT only if surgical margins
were positive, most often within 3 months after surgery, while
43% (51% in WE; P = 0.02) recommended salvage EBRT in
the case of BCR (Fig. 7). Adjuvant ADT was oﬀered only if
lymph nodes were positive by 62% of respondents (73% in SE,
45% in WE; P = 0.01 for both), while salvage ADT was oﬀered
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7
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17
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32
= significantly higher than total
No answer
Others
I don’t perform radical prostatectomy
Laparoscopic approach
Robot-assisted laparoscopic approach
Open retropubic approach
= significantly lower than totalEurope
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Central Easterm
(N = 108)
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(N = 33)
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(N = 280)
Western
(N = 164)
Fig. 3 Preferences for radical prostatectomy
approach for high-risk prostate cancer.
Numbers are proportions of respondents per
geographical area.Total refers to the entire
European sample (N = 585).
Fig. 4 Preferences for pelvic lymph node dissection template at the time of radical prostatectomy for high-risk prostate cancer. Numbers are
proportions of respondents per geographical area.Total refers to the entire European sample (N = 585). LNI, lymph node invasion.
I remove the external, internal and obturator nodes,
bilaterally, in all cases
I remove the external, internal common iliac and
obturator nodes, bilaterally, in all cases
I remove the external, internal common iliac,
obturator and presacral nodes, in all cases
I remove the external, internal common iliac and obturator
nodes, bilaterally, and all the tissue up to the inferior me
I remove the external, internal common iliac and
obturator nodes only on the tumor side
I remove only the suspicious tissue on palpation
I remove the obturator nodes only
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in the case of BCR and distant metastases by 39% (53% in
CEE, 26% in WE; P = 0.02 for both) and 76% (without
signiﬁcant geographical variations) of respondents,
respectively (Fig. 8).
Discussion
The present study is the ﬁrst international survey evaluating
preferences in the management of high-risk PCa among
urologists in Europe. There was good agreement on the
deﬁnition of high-risk disease. The preferred treatment was
found to be open RP with either standard or extended PLND
as the initial step of a multiple-treatment approach. Consensus
on the deﬁnition of disease recurrence after primary
treatment was weaker, and there was much heterogeneity in
administration of adjuvant and salvage therapies. Geographical
diﬀerences were observed with regard to several questionnaire
items.
Several results of our survey may be of interest. First, the
deﬁnition of high-risk PCa was shared by ∼66% of the
respondents. The most commonly used deﬁnition was any
cancer with PSA ≥20 ng/mL or clinical stage ≥ T3 or biopsy
Gleason score ≥ 8, which represents the deﬁnition published
in both the EAU and National Comprehensive Cancer
Network (NCCN) guidelines [4,5].This should facilitate
the conduct of multinational collaborations for trials on
high-risk PCa.
Second, the majority of respondents would oﬀer RP as the
initial step of a multiple-treatment approach for PCa.While
EBRT with long-term ADT has long been considered the
standard of care compared with other treatment methods,
over the past decade there has been a surge in the use of RP as
primary treatment in selected patients, followed by EBRT in
case of adverse pathological features [12]. Both the EAU and
NCCN guidelines [5] recommend radiation therapy with ADT
Fig. 5 Preferences for definition of biochemical recurrence after radical prostatectomy for high-risk prostate cancer. Numbers are proportions of
respondents per geographical area.Total refers to the entire European sample (N = 585).
Any rise of PSA above ≥0.2 ng/mL confirmed
by a 2nd measurement at least 1 month apart
Any rise of PSA above ≥0.2 ng/mL confirmed
by a 2nd measurement at least 1 week apart
Any rise >2 ng/mL above the
post-prostatectomy nadir value
Any rise of PSA above ≥0.4 ng/mL
Any rise of PSA
3 consecutive rises of PSA above ≥0.2 ng/mL
Europe
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7 12 3 162
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Fig. 6 Preferences for definition of local recurrence after radical prostatectomy for high-risk prostate cancer. Numbers are proportions of respondents
per geographical area.Total refers to the entire European sample (N = 585). PET, positron emission tomography.
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as the preferred treatment for high-risk PCa, and indicate
surgery as an option to selected patients with low-volume
disease [4] or no ﬁxation to adjacent organs [5]. The
ﬁndings in the present survey may reﬂect data from recent
population-based studies comparing surgery and EBRT for
clinically localized PCa, which have consistently demonstrated
a possible beneﬁt of surgery, especially in younger and ﬁtter
patients with more aggressive disease [13–16]; however, the
target population of our survey were urologists only, which
may have biased the choice of treatment towards surgery.
Third, the preferred approach for RP is open (58%), followed
by robot-assisted (20%) and laparoscopic (15%). One reason
might be the reluctance of urologists to use newer, i.e. robotic,
technology in patients with an aggressive form of disease, a
ﬁnding common to other settings [17]. In particular, the lack
of tactile feedback with the robotic approach might have led
some surgeons to prefer the open operation for high-risk
cases. Despite the growing body of literature reporting on
favourable outcomes of robot-assisted RP in high-risk PCa
[18], including the evidence that the use of intra-operative
visual cues can compensate for lack of tactile feedback [19],
the absence of well-designed randomised or head-to-head
comparative studies may have generated some uncertainties
among health providers. Alternatively, the limited uptake of
robot-assisted surgery in several countries in Europe,
especially in CEE (where open RP has the highest preference
in our survey), may be attributable to health economic
reasons. These countries have a lower budget assigned for
healthcare and, thus, their interest in investing in costly
technology may be limited. Our survey did not evaluate
whether a robot was available at the respondent’s institution,
and, if available, whether a robot-assisted approach would
have been favoured over the open one for high-risk PCa;
however, in one US study, it has been shown that hospitals
with availability of robotic surgery increased the RP volume
by ∼30 cases/year, while hospitals without robotic facilities
decreased the volume by ∼5 cases/year [20]. It might thus be
anticipated that with increasing dissemination of robotic
systems across Europe, these ﬁgures will change in favour of
the robotic approach.
Fourth, PLND at the time of RP was performed by virtually
all urologists; however, despite the currently accepted
recommendation to systematically perform an extended PLND
in patients with high-risk PCa [4,5], the use of an extended
Fig. 7 Preferences for administration of A, adjuvant and B, salvage external beam radiation therapy after radical prostatectomy for high-risk prostate
cancer. Numbers are proportions of respondents per geographical area.Total refers to the entire European sample (N = 585).
Only if positive surgical margins are
present
At any rise of PSA ≥0.2 ng/mL confirmed
by a second measurement
At any rise of PSA ≥0.4 ng/mL confirmed
by a second measurement
Only after biopsy-proven local
recurrence
At any rise of PSA after radical
prostatectomy
At PSA velocity > 2 ng/mL/year
Others
Only if lymph node invasin is present
PSA rise/recurrence
Stage T3/T4
Biochemical/local recurrence
Others
In the absence of clinically measurable
disease
Only in the absence of biochemically
measurable disease
Europe
(N = 585)
A
B
53 36 63 3757
43 58 39 5136
19 3 24 1024
17 12 22 1017
6 12 2 106
5 6 7 25
6 6 2 146
7 6 9 75
6 6 7 67
6 3 7 211
5 12 2 113
4 3 3 65
13 30 8 245
1 0.4 32
= significantly higher than total
= significantly lower than total
= significantly higher than total
= significantly lower than total
Central Easterm
(N = 108)
Northern
(N = 33)
Southern
(N = 280)
Western
(N = 164)
Europe
(N = 585)
Central Easterm
(N = 108)
Northern
(N = 33)
Southern
(N = 280)
Western
(N = 164)
Plot Area
576
© 2014 The Authors
BJU International © 2014 BJU International
Surcel et al.
and standard template was equally split among surgeons.
Possible reasons not to perform an extended PLND may
be the absence of convincing high-level evidence as to its
curative role [21], and the potential for greater morbidity
[22]. Also, more than one third of respondents considered
that the number of nodes removed was not relevant. This is
consistent with the ﬁndings of recent publications [23,24],
rather emphasising the value of an accurate dissection of
anatomically determined pelvic regions. Additionally, roughly
half of respondents of the minority who routinely perform
frozen sections during PLND reported they abandon surgery
in the case of lymph node metastases. This practice is
reminiscent of the old belief that patients with PCa with
positive lymph nodes have a systemic disease with poor
prognosis, but increasing contemporary evidence suggests that
RP with extended PLND is an important component in
multimodal therapy of locally advanced PCa with the potential
to improve survival [25].
Fifth, there was much heterogeneity in the deﬁnition of
disease recurrence after primary treatment and in the use of
adjuvant and salvage therapies. The lack of consensus on
biochemical and local recurrence has direct implications in the
subsequent choice of adjuvant and salvage treatment, as
disease progression rates may vary by up to 35% depending on
the deﬁnition used [1]. Only 53% of respondents would oﬀer
adjuvant EBRT in the presence of positive surgical margins,
while 43% would consider salvage EBRT after any rise in
PSA level ≥0.2 ng/mL conﬁrmed by a second measurement.
Accumulating evidence from randomised trials indicates that
adjuvant EBRT to the prostate bed after RP favourably
inﬂuences the course of disease compared with observation
in men with adverse pathological features [26]. No similar
high-level evidence for salvage EBRT is available, however,
although in some observational studies a substantial
proportion of patients with high-risk PCa showed a durable
response to salvage EBRT, provided that it was administered
at the earliest evidence of BCR [27]. Potential concerns
discouraging surgeons from adopting an immediate EBRT
policy are the detrimental eﬀect on the functional status (i.e.
recovery of urinary continence and potency) [26,27], and the
risk of overtreatment for many patients who would have never
recurred or progressed in the absence of EBRT [26].
Sixth, considerable geographical diﬀerences do exist with
regard to various aspects of high-risk PCa management. A
Fig. 8 Preferences for administration of A, adjuvant and B, salvage androgen deprivation treatment after radical prostatectomy for high-risk prostate
cancer. Numbers are proportions of respondents per geographical area.Total refers to the entire European sample (N = 585).
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similar scenario has been described among urologists of
North America [28], as well as for the management of other
malignancies, such as breast cancer [29]. Possible reasons are
disparities in national health systems, the availability of
diagnostic and therapeutic technologies and cultural
background.
The present study has some limitations. First, it is subject to
volunteer bias, as the majority of invited participants did not
respond. Also, there was no pre-determined sample size that
was equally representative of each of the four geographical
areas in Europe. Respondents from SE accounted for roughly
half of the European sample, with the potential to unbalance
the results. Furthermore, diﬀerences in management patterns
within the geographical area were not assessed. It might well
be that signiﬁcant diﬀerences in management exist even
within the same country. Second, we only focused on
urologists and did not include radiation and medical
oncologists, which could have led to specialty bias. In a
recent national US survey on physician attitudes towards
localized PCa [30], in fact, it was shown that urologists
and radiation oncologists had diﬀerent treatment
preferences and perception of oncological and functional
outcome, with implications potentially relevant to treatment
recommendations and patient counselling. Third, the
majority of the respondents were urologists practising in
academic and tertiary referral centres, which may have
diﬀerent resources and technologies available compared with
those practising at regional/county hospitals. Fourth, reasons
for individual choice of one treatment over another (e.g.
patient age, comorbidity and preferences, or surgeon/hospital
experience) were not investigated for either the primary
tumour or its recurrence.
In conclusion, with the limitation of a low response rate, the
present study is the ﬁrst international survey to evaluate
patterns of management of high-risk PCa among urologists
in Europe. Although deﬁnition of high-risk PCa was uniform
and consistent with common guidelines, the use of RP as
the initial step of a multiple-treatment approach, the
adoption of a standard PLND template as frequently as
an extended one, and a deferred EBRT policy for disease
recurrence represent deviations in practice from the
guideline recommendations, and warrant further exploration.
Moreover, considerable geographical variations in patterns
of staging and treatment were observed. This phenomenon
may be attributable to the absence of high-level evidence,
coupled with variability in local medical infrastructure
availability. Whether these diﬀerences in standard of
care might aﬀect oncological outcomes requires further
study.
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